
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Click the title above for a link to open the Pharmaceutical Executive April 2021 issue in an interactive PDF format.
over 5 years ago
The Challenges of Worker Qualification Management in Pharmaover 5 years ago
Years in the Making: A Repeat Recognition—Uninterruptedover 5 years ago
Pharm Exec at 40 (1990-1993)over 5 years ago
The Power of Parityover 5 years ago
No Limits to Science, Or Selfover 5 years ago
In Silico in Sight as Biopharma Game-Changerover 5 years ago
Long-View Innovation Hopes for Pharma Policy in the EU





